BIOME AUSTRALIA LIMITED (BIO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BIO

BIO - BIOME AUSTRALIA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Household & Personal Products
Debt/EBITDA: 11.04
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.245

25 Jun
2026

-0.010

OPEN

$0.26

-3.92%

HIGH

$0.26

191,431

LOW

$0.25

TARGET
$1.00 308.2% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
BIO: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 1.6 1.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx 100.0% - 1.2% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 24.4 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx1.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx23.9 M
Book Value Per Share xxxxxxxxxxxxxxx4.1
Net Operating Cash Flow xxxxxxxxxxxxxxx1.6 M
Net Profit Margin xxxxxxxxxxxxxxx15.11 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx51.34 %
Return on Invested Capital xxxxxxxxxxxxxxx48.39 %
Return on Assets xxxxxxxxxxxxxxx26.07 %
Return on Equity xxxxxxxxxxxxxxx51.34 %
Return on Total Capital xxxxxxxxxxxxxxx17.89 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx3 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx4 M
Price To Book Value xxxxxxxxxxxxxxx6.44

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx2.05 %
Cost of Goods Sold xxxxxxxxxxxxxxx17 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx5 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

04/06/2026

1

Buy

$1.00

308.16%

Biome Australia is introducing contract manufacturing in its home market of Australia, to assemble and package its activated probiotics range. The initial two-year term with Specialty Probiotics Australia is on an exclusive basis and subject to meeting quality and delivery standards.

The company will retain EU supply arrangements for EU markets. There is no upfront expenditure required for the contract and gross margins are expected to rise to more than 65% over 18 months from the first batch in September, along with eliminating extended sea freight time.

Bell Potter does not change estimates and awaits evidence of gross margin improvement but believes, conceptually, this is a positive development that should enhance operating leverage.

Buy rating and $1 target are unchanged.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.50 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 3.30 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

BIO STOCK CHART

FNArena News on BIO

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL: Buy Trigger Ahead

Apr 26 2022 - Technicals
2
Why CSL Fell Sharply Yesterday

Dec 17 2021 - Australia
3
Beating The Biotech Blues

Sep 14 2021 - International
4
Uncertainty Prevails For CSL

Aug 19 2021 - Australia
5
Flying High – Medicinal Marijuana In Australia

Jul 26 2021 - Australia
6
Wesfarmers On Drugs?

Jul 13 2021 - Australia
7
Is CSL’s Plasma Recovery Now Priced In?

Jun 23 2021 - Australia
8
CSL: Buy The Dip

Jun 22 2021 - Technicals
9
CSL To Retest Its High?

May 25 2021 - Technicals
10
Treasure Chest: CSL Plasma At Turning Point?

May 05 2021 - Treasure Chest